- SEC FilingOn Thursday, October 12, 2023, Vigil Neuroscience, Inc. (the "Company") provided an update on the Company's small molecule TREM2 agonist, VG-3927. The Company announced that it received the 30-day
- Announced VG-3927 as lead candidate to enter clinical development for potential treatment of Alzheimer's Disease -- IND for VG-3927 now open; Phase 1 clinical trial in healthy volunteers allowed to proceed with partial
Gainers
Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider.